Asieris Pharmaceuticals Releases 2024 Annual Report, with Revenue Exceeding RMB 200M in 1st Year of Commercialization and Innovative Portfolio Accelerating Toward Launch
April 18, 2025 Asieris Pharmaceuticals Releases 2024 Annual Report, with Revenue Exceeding RMB 200M in 1st Year of Commercialization and Innovative Portfolio Accelerating Toward Launch
March 27, 2025 Asieris’ Subsidiary Baylink Biosciences to Present Two Research Achievements at the 2025 American Association for Cancer Research Annual Meeting
March 26, 2025 Asieris’ Research Achievements Selected for Presentation at the 2025 American Association for Cancer Research Annual Meeting
March 13, 2025 Asieris’ APL-2302 Completes First Patient Enrollment in Clinical Trial for Advanced Solid Tumors
February 14, 2025 Asieris Presents Phase II Clinical Study Results of APL-1202 in Combined with PD-1 Inhibitor Tislelizumab as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer at 2025 ASCO-GU
January 24, 2025 Asieris Selected as the Top 10 Exhibitors with Communication Influence” in the Innovation Incubation Special Section of the 7th CIIE